# US 2019/0376948 A1 · Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376948 A1
- Document ID: US20190376948A1
- Status: Published application
- Kind: A1
- Application number: 16/545,349
- Filed: 2019-08-20
- Published: 2019-12-12
- Earliest claimed: 2016-03-14
- Inventors: Bruce R. Yacyshyn; Mary E. Yacyshyn
- Web page: https://patentgrep.com/patent/US20190376948A1

## CPC

- G01N 33/492: {Determining multiple analytes}
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/606: having amino groups
- G01N 2800/065: Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
- G01N 2800/067: Pancreatitis or colitis
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified predictive target biomarkers associated with predicting the risk of an individual developing IBD and includes one or more predictive panels of prediction target biomarkers that are used to determine the risk of an individual developing IBD for determining if a therapy should be administered to reduce the risk and further determines the efficacy of treating the individual with mesalamine and effectively identifies and validates novel drug targets for new IBD therapeutics, new diagnostics and diagnostics standards for IBD therapeutic strategies.

## Claims

### Claim 1

A process of identifying individuals that may have or have a high risk of developing inflammatory bowel disease (IBD) prior to diagnosis of IBD, the process comprises the steps of:
identifying an individual to be tested;
obtaining a first blood sample of the individual;
selecting a panel of predictive target biomarkers;
examining the blood sample to obtain a level of each predictive target biomarker listed on the panel of predictive target biomarkers;
determining the total level of protein in the blood sample;
selecting a prediction logistic regression model for predicting the risk of an individual developing IBD and using the selected logistic regression model and the levels of each predictive target biomarker and the total level of protein in the blood sample to calculate a risk value; and
determining if the risk value is above or below a cut-off value for the selected prediction logistic regression model;
wherein if the risk value is greater than the cut-off value, the process includes the step of administering a therapy to reduce the risk of the individual developing IBD; and
wherein if the risk value is below the cut-off value the process includes the step of administering a therapy to monitor the individual for detecting an increase in the risk of developing IBD.

### Claim 2 (depends on 1)

The process of claim 1 wherein if the risk value of the individual developing IBD is greater than the cut-off value, the process includes the steps of:
selecting a panel of predictive target biomarkers for use in determining the risk of the individual developing Crohn's disease;
examining the blood sample to obtain a level of each predictive target biomarker listed on the panel of predictive target biomarkers for use in determining the risk of the individual developing Crohn's disease;
selecting a prediction logistic regression model for use in determining the risk of the individual developing Crohn's disease and using the logistic regression model and the levels of each predictive target biomarker listed on the panel of predictive target biomarkers for use in determining the risk of the individual developing Crohn's disease and the total level of protein in the blood sample to calculate a risk value for developing Crohn's disease;
determining if the risk value for developing Crohn's disease is above or below a cut-off value for the prediction logistic regression model for use in determining the risk of the individual developing Crohn's disease;
wherein if the risk value for developing Crohn's disease is greater than the cut-off value for the prediction logistic regression model for use in determining the risk of the individual developing Crohn's disease, the process includes the step of administering a therapy to reduce the risk of developing Crohn's disease;
wherein if the risk value for developing Crohn's disease is below the cut-off value for the prediction logistic regression model for use in determining the risk of the individual developing Crohn's disease, the process includes the step of administering a therapy to monitor the individual for detecting an increase in the risk of developing Crohn's disease.

### Claim 3 (depends on 1)

The process of claim 1 wherein if the risk value for the individual developing IBD is greater than the cut-off value, the process includes the steps of:
selecting a panel of predictive target biomarkers for use in determining the risk of the individual developing ulcerative colitis (UC);
examining the blood sample to obtain a level of each predictive target biomarker listed on the panel of predictive target biomarkers for use in determining the risk of the individual developing UC;
selecting a prediction logistic regression model for use in determining the risk of the individual developing UC and using the logistic regression model and the levels of each predictive target biomarker listed on the panel of predictive target biomarkers for use in determining the risk of the individual developing UC and the total level of protein in the blood sample to calculate a risk value for developing UC;
determining if the risk value for developing UC is above or below a cut-off value for the prediction logistic regression model for use in determining the risk of the individual developing UC;
wherein if the risk value for developing UC is greater than the cut-off value for the prediction logistic regression model for use in determining the risk of the individual developing UC disease, the process includes the step of administering a therapy to reduce the risk of developing UC;
wherein if the risk value for developing UC is below the cut-off value for the prediction logistic regression model for use in determining the risk of the individual developing UC, the process includes the step of administering a therapy to monitor the individual for detecting an increase in the risk of developing UC.

### Claim 4 (depends on 1)

The process of claim 1 wherein if the risk value for the individual developing IBD is greater than the cut-off value, the process includes the step of predicting the effectiveness of mesalamine treatment for the individual.

### Claim 5 (depends on 1)

The process of claim 1 wherein if the risk value for the individual developing IBD is greater than the cut-off value, the process further includes the step of using a blood sample from the individual to determine if mesalamine therapy will be effective or if an alternate therapy should be administered to the individual.

### Claim 6 (depends on 1)

The process of claim 1 wherein the prediction target biomarkers panel for use in predicting the risk of the individual developing IBD, without environmental change and/or impactful stress being considered, comprises protein predictive target biomarkers of HP, GCSF, RETN, CRP, sICAM and antibody target biomarkers antibody to tetanus toxoid and identifies the relationships of sICAM×HP, GCSF×CRP and GCSF×RETN.

### Claim 7 (depends on 1)

The process of claim 1 wherein the prediction logistic regression model for determining the risk value for developing IBD without considering environmental change and/or impactful stress is: Log (p/1ip)=−641.8833706+71.65755693×Haptoglobin−41.87442414×GCSF−45.27490174×RETN−16.22723673×CRP−1.029456032×Antibody TT+14.476981343×sICAM+5.667294456×(sICAM×Haptoglobin)−0.80715758×(GCSF×CRP)−2.288843531×(GCSF×RETN).

### Claim 8 (depends on 1)

The process of claim 1 for identifying individuals that may have or have a high risk of developing inflammatory bowel disease (IBD), wherein the prediction target biomarkers panel for use in predicting the risk of the individual developing IBD with environmental change and/or impact stress being considered comprises protein predictive target biomarkers of sICAM, GCSF, HP, CRP, RETN and antibody target biomarkers antibody to tetanus toxoid.

### Claim 9 (depends on 1)

The process of claim 1 wherein the prediction logistic regression model for determining the risk value for developing IBD with considering environmental change and/or impactful stress is: Log (p/1ip)=1101.571616−0.813305575×deployment−104.1257102×sICAM−62.63858365×GCSF−5.604142451×sICAM×GCSF+65.611507602×HP+5.107130532×sICAM×HP−36.81637743×TT−1.711888269×GCSF×TT+0.767135503×CRP+1.770741857×RETN.

### Claim 10 (depends on 2)

The process of claim 2 wherein the panel of predictive target biomarkers for use in determining the risk of the individual developing Crohn's disease comprises protein predictive target biomarkers of SCL70, AcE, RETN, CRP, GCSF and an antibody target biomarker of antibody to tetanus toxoid (TT) and identifies the relationships of sICAM×RETN, GCSF×TT.

### Claim 11 (depends on 2)

The process of claim 2 wherein the prediction logistic regression model for determining the risk value for developing Crohn's disease is Log (p/1ip)=−174.4+171.2×SLC70−4.0×AcE−32.2×RETN+1.1×CRP+15.9×GCSF−57.4×TT+11.6×(sICAM×RETN)−2.7×(GCSF×TT).

### Claim 12 (depends on 3)

The process of claim 3 wherein the panel of predictive target biomarkers for use in determining the risk of the individual developing UC comprises protein predictive target biomarkers of HP, SICAM1 and RETN, and identifies the relationship of sICAM1×HP.

### Claim 13 (depends on 3)

The process of claim 3 wherein the prediction logistic regression model for determining the risk value for developing UC is Log (p/1−p)=221.7+2.2×Resistin+15.1×sICAM+61.5×Haptoglobin+4.9×(sICAM×Haptoglobin).

### Claim 14

A process of identifying individuals that may have or have a high risk of developing inflammatory bowel disease (IBD) prior to diagnosis of IBD, the process comprises the steps of:
identifying an individual to be tested;
obtaining a first blood sample of the individual;
selecting a panel of predictive target biomarkers for IBD;
examining the blood sample to obtain a level of each predictive target biomarker listed on the panel of predictive target biomarkers for IBD;
determining the total level of protein in the blood sample;
selecting a prediction logistic regression model for predicting the risk of an individual developing IBD and using the selected logistic regression model for predicting the risk of an individual developing IBD and the levels of each predictive target biomarker listed on the panel of predictive target biomarkers for IBD and the total level of protein in the blood sample to calculate a risk value for the individual developing IBD; and
determining if the risk value for the individual developing IBD is above or below a cut-off value for the selected prediction logistic regression model for predicting the risk of an individual developing IBD;
wherein if the risk value for the individual developing IBD is below the cut-off value the process includes the step of determining if a therapy to monitor the individual for detecting an increase in the risk of developing IBD should be administered;
wherein if the risk value for the individual developing IBD is greater than the cut-off value, the process includes the steps of:
selecting a panel of predictive target biomarkers for use in determining the risk of the individual developing Crohn's disease;
examining the blood sample to obtain a level of each predictive target biomarker listed on the panel of predictive target biomarkers for use in determining the risk of the individual developing Crohn's disease;
selecting a prediction logistic regression model for use in determining the risk of the individual developing Crohn's disease and using the logistic regression model and the levels of each predictive target biomarker listed on the panel of predictive target biomarkers for use in determining the risk of the individual developing Crohn's disease and the total level of protein in the blood sample to calculate a risk value for developing Crohn's disease;
determining if the risk value for developing Crohn's disease is above or below a cut-off value for the prediction logistic regression model for use in determining the risk of the individual developing Crohn's disease;
wherein if the risk value for developing Crohn's disease is greater than the cut-off value for the prediction logistic regression model for use in determining the risk of the individual developing Crohn's disease, the process includes the step of administering a therapy to reduce the risk of developing Crohn's disease; and
wherein if the risk value for developing Crohn's disease is below the cut-off value for the prediction logistic regression model for use in determining the risk of the individual developing Crohn's disease, the process includes the steps of selecting a panel of predictive target biomarkers for use in determining the risk of the individual developing ulcerative colitis (UC);
examining the blood sample to obtain a level of each predictive target biomarker listed on the panel of predictive target biomarkers for use in determining the risk of the individual developing UC;
selecting a prediction logistic regression model for use in determining the risk of the individual developing UC and using the logistic regression model and the levels of each predictive target biomarker listed on the panel of predictive target biomarkers for use in determining the risk of the individual developing UC and the total level of protein in the blood sample to calculate a risk value for developing UC;
determining if the risk value for developing UC is above or below a cut-off value for the prediction logistic regression model for use in determining the risk of the individual developing UC;
wherein if the risk value for developing UC is greater than the cut-off value for the prediction logistic regression model for use in determining the risk of the individual developing UC disease, the process includes the step of administering a therapy to reduce the risk of developing UC; and
wherein if the risk value for developing UC is below the cut-off value for the prediction logistic regression model for use in determining the risk of the individual developing UC, the process includes the step of determining if a therapy to monitor the individual for detecting an increase in the risk of developing UC should be adminstered.

### Claim 15 (depends on 14)

The process of claim 14 wherein if the risk value for the individual developing IBD is greater than the cut-off value, the process includes the step of predicting the effectiveness of mesalamine treatment for the individual.

### Claim 16 (depends on 14)

The process of claim 14 wherein if the risk value for the individual developing IBD is greater than the cut-off value, the process further includes the step of using a blood sample from the individual to determine if mesalamine therapy will be effective or if an alternate therapy should be administered to the individual.

### Claim 17 (depends on 14)

The process of claim 14 wherein the prediction target biomarkers panel for use in predicting the risk of the individual developing IBD, without environmental change and/or impactful stress being considered, comprises protein predictive target biomarkers of HP, GCSF, RETN, CRP, sICAM and antibody target biomarker of antibody to tetanus toxoid and identifies the relationships of sICAM×HP, GCSF×CRP and GCSF×RETN.

### Claim 18 (depends on 14)

The process of claim 14 wherein the prediction logistic regression model for determining the risk value for developing IBD without considering environmental change and/or impactful stress is: Log (p/1ip)=−641.8833706+71.65755693×Haptoglobin−41.87442414×GCSF−45.27490174×RETN−16.22723673×CRP−1.029456032×Antibody TT+14.476981343×sICAM+5.667294456×(sICAM×Haptoglobin)−0.80715758×(GCSF×CRP)−2.288843531×(GCSF×RETN).

### Claim 19 (depends on 14)

The process of claim 14 for identifying individuals that may have or have a high risk of developing inflammatory bowel disease (IBD), wherein the prediction target biomarkers panel for use in predicting the risk of the individual developing IBD with environmental change and/or impactful stress being considered comprises protein predictive target biomarkers of sICAM, GCSF, HP, CRP, RETN and antibody target biomarkers antibody to tetanus toxoid.

### Claim 20 (depends on 14)

ess of claim 14 wherein the prediction logistic regression model for determining the risk value for developing IBD with considering of environmental change and/or impactful stress is: Log (p/1ip)=1101.571616−0.813305575×deployment−104.1257102×sICAM−62.63858365×GCSF−5.604142451×sICAM×GCSF+65.611507602×HP+5.107130532×sICAM×HP−36.81637743×TT−1.711888269×GCSF×TT+0.767135503×CRP+1.770741857×RETN.

### Claim 21 (depends on 14)

The process of claim 14 wherein the panel of predictive target biomarkers for use in determining the risk of the individual developing Crohn's disease comprises protein predictive target biomarkers of SCL70, AcE, RETN, CRP, GCSF and antibody target biomarker of antibody to tetanus toxoid (TT) and identifies the relationships of sICAM×RETN, GCSF×TT.

### Claim 22 (depends on 14)

The process of claim 14 wherein the prediction logistic regression model for determining the risk value for developing Crohn's disease is Log (p/1ip)=−174.4+171.2×SLC70−4.0×AcE−32.2×RETN+1.1×CRP+15.9×GCSF−57.4×TT+11.6×(sICAM×RETN)−2.7×(GCSF×TT).

### Claim 23 (depends on 14)

The process of claim 14 wherein the panel of predictive target biomarkers for use in determining the risk of the individual developing UC comprises protein predictive target biomarkers of HP, SICAM1 and RETN, and identifies the relationship of sICAM1×HP.

### Claim 24 (depends on 14)

The process of claim 14 wherein the prediction logistic regression model for determining the risk value for developing UC is Log (p/1−p)=221.7+2.2×Resistin+15.1×sICAM+61.5×Haptoglobin+4.9×(sICAM×Haptoglobin).
